Form 4/A for ATOS ATOSSA THERAPEUTICS, INC.
Accepted 2026-01-30 00:00:00 ET · period of report 2026-01-20 · accession 0001193125-26-030571 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DA | 2026-01-30 | 2026-01-20 | ATOS | QUAY STEVEN C | Pres, CEO, Dir | A - Grant | $0.00 | +331.7K | 345.6K | +2,386% | $0 |
| DA | 2026-01-30 | 2026-01-20 | ATOS | QUAY STEVEN C | Pres, CEO, Dir | A - Grant | $0.6 | +950.0K | 950.0K | New | +$570.0K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-01-20 | A | A | 331,674 | $0.00 | 345,572 | D | — | — | (F1) Represents the acquisition of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs shall vest one year from the Transaction Date. (F2) The original Form 4, filed on January 22, 2026, is being amended by this Form 4 amendment solely to correct an administrative error regarding the number of RSUs acquired. |
| 2 | Derivative | Stock Options (right to buy) | 2026-01-20 | A | A | 950,000 | $0.6 | 950,000 | D | $0.6 · — to 2026-01-20 | 950,000 Common Stock | (F4) The options shall vest on a quarterly basis over 24 months following January 20, 2026, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date. The options were issued on January 20, 2026, with an exercise price of $0.603, representing the closing stock price on January 20, 2026. |